Recent changes
Track the most recent changes to the wiki on this page.
15 May 2021
| 21:18 | Peripheral T-cell lymphoma (diff | hist) . . (+2) . . Warner-admin (talk | contribs) |
| 21:18 | Pancreatic cancer (5 changes | history) . . (-3,431) . . [Warner-admin; Jwarner (4×)] | ||
| 21:18 (cur | prev) . . (+1) . . Warner-admin (talk | contribs) | |||
| m | 09:48 (cur | prev) . . (+30) . . Jwarner (talk | contribs) (→Gemcitabine monotherapy {{#subobject:4f0be9|Regimen=1}}) | ||
| m | 09:47 (cur | prev) . . (-1,598) . . Jwarner (talk | contribs) (→FLEC {{#subobject:a6c123|Regimen=1}}) | ||
| m | 09:46 (cur | prev) . . (+30) . . Jwarner (talk | contribs) (→Regimen variant #2, 1000 mg/m2, 8-week lead-in ("Burris regimen") {{#subobject:5d6dd0|Variant=1}}) | ||
| m | 09:45 (cur | prev) . . (-1,894) . . Jwarner (talk | contribs) (→PEFG {{#subobject:f0e123|Regimen=1}}) |
| 21:17 | Chronic lymphocytic leukemia (2 changes | history) . . (+16) . . [Warner-admin (2×)] | ||
| 21:17 (cur | prev) . . (+1) . . Warner-admin (talk | contribs) | |||
| m | 12:05 (cur | prev) . . (+15) . . Warner-admin (talk | contribs) (Text replacement - "IV continuous infusion on days 1 to 7" to "IV continuous infusion over 7 days, started on day 1") (Tags: Mobile edit, Mobile web edit) |
| 21:04 | Multiple myeloma, consolidation and maintenance (4 changes | history) . . (+33) . . [Jwarner; Warner-admin (3×)] | ||
| 21:04 (cur | prev) . . (+5) . . Warner-admin (talk | contribs) (→Targeted therapy) | |||
| m | 21:04 (cur | prev) . . (+5) . . Warner-admin (talk | contribs) (→Targeted therapy, maintenance) | ||
| m | 14:27 (cur | prev) . . (+16) . . Jwarner (talk | contribs) | ||
| 08:24 (cur | prev) . . (+7) . . Warner-admin (talk | contribs) (→Bortezomib monotherapy {{#subobject:dd778e|Regimen=1}}) |
| m 14:28 | Multiple myeloma - historical (diff | hist) . . (+15) . . Jwarner (talk | contribs) (→Regimen variant #5, 0.4/9/40 (bolus doxorubicin & vincristine, dex 12 days/cycle in cycles 1-3) {{#subobject:20136a|Variant=1}}) |
| m 14:27 | Multiple myeloma, induction (diff | hist) . . (+68) . . Jwarner (talk | contribs) |
| m 14:25 | Burkitt lymphoma (2 changes | history) . . (-8) . . [Warner-admin; Jwarner] | ||
| m | 14:25 (cur | prev) . . (-4) . . Jwarner (talk | contribs) (→Untreated) | ||
| m | 08:09 (cur | prev) . . (-4) . . Warner-admin (talk | contribs) (Text replacement - "(160/800 mg)" to "160/800 mg") (Tags: Mobile edit, Mobile web edit) |
| 12:36 | Langerhans cell histiocytosis (diff | hist) . . (+24) . . Warner-admin (talk | contribs) |
| 12:36 | Gastric cancer (2 changes | history) . . (+106) . . [Warner-admin (2×)] | ||
| 12:36 (cur | prev) . . (+88) . . Warner-admin (talk | contribs) | |||
| 12:33 (cur | prev) . . (+18) . . Warner-admin (talk | contribs) |
| m 12:34 | Breast cancer, HER2-positive (diff | hist) . . (+22) . . Warner-admin (talk | contribs) |
| 12:31 | Colon cancer (2 changes | history) . . (+48) . . [Warner-admin (2×)] | ||
| 12:31 (cur | prev) . . (+48) . . Warner-admin (talk | contribs) (→Chemotherapy) | |||
| 12:14 (cur | prev) . . (0) . . Warner-admin (talk | contribs) |
| 12:29 | Melanoma (2 changes | history) . . (+105) . . [Warner-admin (2×)] | ||
| 12:29 (cur | prev) . . (+121) . . Warner-admin (talk | contribs) (→IL-2 monotherapy {{#subobject:fa72a9|Regimen=1}}) | |||
| m | 12:20 (cur | prev) . . (-16) . . Warner-admin (talk | contribs) (→Immunotherapy, pulse cycles (2, 3, 5, 6, 8, 10, 12)) |
| 12:16 | Ovarian cancer (diff | hist) . . (+4) . . Warner-admin (talk | contribs) |
| 12:14 | Head and neck cancer (diff | hist) . . (0) . . Warner-admin (talk | contribs) |
| 12:13 | Anal cancer (diff | hist) . . (+33) . . Warner-admin (talk | contribs) |
| m 12:12 | Esophageal adenocarcinoma (diff | hist) . . (-4) . . Warner-admin (talk | contribs) (Text replacement - "m<sup>2</sup> )" to "m<sup>2</sup>)") |
| m 12:11 | Esophageal cancer (diff | hist) . . (-1) . . Warner-admin (talk | contribs) (Text replacement - "m<sup>2</sup> )" to "m<sup>2</sup>)") |
| m 12:11 | Esophageal squamous cell carcinoma (diff | hist) . . (-3) . . Warner-admin (talk | contribs) (Text replacement - "m<sup>2</sup> )" to "m<sup>2</sup>)") |
| 12:08 | Penile cancer (diff | hist) . . (-14) . . Warner-admin (talk | contribs) (→PCF {{#subobject:edc2a7|Regimen=1}}) |
| m 12:04 | Editing test page (diff | hist) . . (+15) . . Warner-admin (talk | contribs) (Text replacement - "IV continuous infusion on days 1 to 7" to "IV continuous infusion over 7 days, started on day 1") |
| m 12:04 | Acute myeloid leukemia, FLT3-positive (diff | hist) . . (+30) . . Warner-admin (talk | contribs) (Text replacement - "IV continuous infusion on days 1 to 7" to "IV continuous infusion over 7 days, started on day 1") (Tags: Mobile edit, Mobile web edit) |
| m 11:50 | Drug index (diff | hist) . . (+11) . . Jwarner (talk | contribs) (→Interesting and Helpful Links) |
| m 11:49 | Tutorial (diff | hist) . . (-94) . . Jwarner (talk | contribs) (→Interesting and helpful links) |
| m 09:57 | Iptacopan (LNP023) (2 changes | history) . . (+179) . . [Jwarner (2×)] | ||
| m | 09:57 (cur | prev) . . (+61) . . Jwarner (talk | contribs) | ||
| m | 09:51 (cur | prev) . . (+118) . . Jwarner (talk | contribs) |
| m 09:47 | Pancreatic cancer - historical (2 changes | history) . . (+3,622) . . [Jwarner (2×)] | ||
| m | 09:47 (cur | prev) . . (+1,678) . . Jwarner (talk | contribs) (→Metastatic disease, first-line) | ||
| m | 09:45 (cur | prev) . . (+1,944) . . Jwarner (talk | contribs) (→Metastatic disease, all lines of therapy) |
| m 09:42 | Paroxysmal nocturnal hemoglobinuria (diff | hist) . . (+27) . . Jwarner (talk | contribs) (→Investigational agents) |
| m 09:03 | Bladder cancer (diff | hist) . . (-4) . . Warner-admin (talk | contribs) (Text replacement - "IV or oral equivalent" to "IV or PO equivalent") (Tags: Mobile edit, Mobile web edit) |
| m 08:11 | Hodgkin lymphoma (diff | hist) . . (-2) . . Warner-admin (talk | contribs) (Text replacement - "(160/800 mg)" to "160/800 mg") |
| m 08:10 | HIV-associated lymphoma (diff | hist) . . (-2) . . Warner-admin (talk | contribs) (Text replacement - "(160/800 mg)" to "160/800 mg") |
| m 08:10 | Hodgkin lymphoma, nodular lymphocyte-predominant (diff | hist) . . (-8) . . Warner-admin (talk | contribs) (Text replacement - "(160/800 mg)" to "160/800 mg") |
| m 08:09 | B-cell acute lymphoblastic leukemia (diff | hist) . . (-8) . . Warner-admin (talk | contribs) (Text replacement - "(160/800 mg)" to "160/800 mg") |
| m 08:09 | B-cell acute lymphoblastic leukemia, Ph-positive (diff | hist) . . (-12) . . Warner-admin (talk | contribs) (Text replacement - "(160/800 mg)" to "160/800 mg") |
| m 08:09 | Autologous HSCT (diff | hist) . . (-2) . . Warner-admin (talk | contribs) (Text replacement - "(160/800 mg)" to "160/800 mg") (Tags: Mobile edit, Mobile web edit) |
14 May 2021
| 17:09 | Paroxysmal nocturnal hemoglobinuria (2 changes | history) . . (+1,389) . . [Karine (2×)] | ||
| 17:09 (cur | prev) . . (+1,298) . . Karine (talk | contribs) (iptacopan Lancet study regimen and reference) | |||
| m | 16:55 (cur | prev) . . (+91) . . Karine (talk | contribs) (investigational agents for PNH) (Tag: Visual edit) |
| m 16:48 | Iptacopan (LNP023) (diff | hist) . . (+330) . . Karine (talk | contribs) (Iptacopan drug index info continued) |
